Additionally, radiographic responses are rare for Bevacizumab refractory disease, and this is especially true following multiple bevacizumab regimens. In this phase II study, despite a heavily pretreated population including over half with three prior regimens and an additional quarter with 4 or more regimens, a statistically significant difference in progression free survival at 4 months and Kaplan-Meier estimate for progression was observed which suggests some activity of Evofosfamide in this difficult to treat population. The similarities between the Quant study and our study include the fact that the study population in both cases was heavily pre-treated with 70% of participants in the former study and 77% in the latter having received 3 or more prior chemotherapeutic regiments, also in both studies, the median age of the subjects was similar (47 in our study versus 50 in the Quant study). Also, in both studies there was no exclusion of participants based on number of episodes of progressive disease. The key difference in the study participants, however, is that our study only enrolled recurrent glioblastoma whereas the Quant study included all recurrent malignant gliomas of which only 65% of participants had glioblastoma. In addition, the majority of our study subjects had ECOG scores of 0-1, as compared to the Quant study subjects who's median KPS score was 70 (which is equivalent to ECOG score of 2), and data was not available regarding IDH mutation status for the Quant study